Skip to main content

Spruce Biosciences, Inc.

SPRB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001683553

No open-market purchases or sales by Spruce Biosciences, Inc. insiders were filed in the last 90 days; 65 institutions reported holding it in 13F filings for Q2 2026, worth $116.3M in total; no superinvestor holds it.

Q2 2023 vs. Q1 2023

How the institutions holding Spruce Biosciences, Inc. changed between Q1 2023 and Q2 2023.

All holders in Q2 2023All holders in Q1 2023

13F holders of SPRB: Q1 2023 compared with Q2 2023
MeasureQ1 2023Q2 2023Change
Holders4439−5
Shares33.8M32.0M−1.79M (−5.3%)
Value$74.5M$68.7M−$5.80M (−7.8%)

New holders (4)

Institutions that held Spruce Biosciences, Inc. at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to SPRB in Q2 2023
InstitutionSharesValue% of portfolio
Acuitas Investments, LLC275,006$591.3K0.34%
Sofinnova Investments, Inc.58,029$124.8K0.01%
Charles Schwab Investment Management Inc15,289$32.9K0.00%
Caldwell Sutter Capital, Inc.1,000$2.15K0.00%

Sold out (9)

Institutions that held Spruce Biosciences, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.

Institutions that sold out of SPRB in Q2 2023
InstitutionShares, Q1 2023Value, Q1 2023
CVI Holdings, LLC472,000$1.04M
Goldman Sachs Group Inc182,656$403.7K
Virtu Financial LLC13,722$30.0K
HRT Financial LP13,340$29.0K
Barclays PLC7,484$16.5K
Federated Hermes, Inc.1,032$2.28K
TCI Wealth Advisors, Inc.250$553
Bank of America Corp249$550
FMR LLC50$111